A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

Columbus’ John B Amos Cancer Center is now leading the way to administer a new cancer treatment in the Peach State.The ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...

Brandow, who learned she had stage 4 lymphoma in 2020 after giving birth to her younger son, wants to lift barriers to health ...

Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Brist ...

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.